Acute m2 myeloid leukemia scientific name is acute myeloid leukemia type m2, its survival time can not be generalized, the specific survival time is related to the severity of the disease, treatment status and other factors. 1. Acute myeloid leukemia type m2 can lead to abnormal changes in the peripheral blood of primitive cells and primitive cells, the treatment is more difficult, if you do not receive treatment or poor efficacy, the disease may not be effectively controlled, thus endangering life, usually only a few months of survival time. 2. Some patients with mild disease and relatively slow progress can effectively control their disease after standardized treatment, and their survival time will be prolonged, and they can survive for 3~5 years or even 8~10 years. 3. If bone marrow transplantation is performed, the patient’s own hematopoietic system can be rebuilt, and the normal blood condition can be restored, so the patient can survive for a longer period of time. Of course, infection or rejection may occur after bone marrow transplantation, which is life-threatening. Specific therapeutic drugs include cytarabine, Zoerythromycin, Decitabine, Azacitidine, Vinaclat and so on. Patients are advised to build up confidence, actively go to the hospital and receive standardized treatment under the guidance of physicians.